Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

PHASE4TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Lisdexamfetamine

Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.

Trial Locations (1)

95817

UC Davis MIND Institute, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

University of California, Davis

OTHER

NCT02170298 - Lisdexamfetamine's Effect In ADHD in the Brain and Cognition | Biotech Hunter | Biotech Hunter